

Emerging growth company “

1

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. "

In this report, "Array BioPharma," "Array," "we," "us" and "our" refer to Array BioPharma Inc., unless the context otherwise provides.

Item 7.01 Regulation FD Disclosure.

On March 18, 2019, Array BioPharma Inc. issued a press release announcing that the National Comprehensive Cancer Network[®] (NCCN[®]) has updated the Clinical Practice Guidelines in Oncology for Colon and Rectal Cancer to include BRAFTOVI[®] in combination with MEKTOVI[®] and cetuximab or panitumumab as a Category 2a treatment for patients with BRAF^{V600E}-mutant metastatic colorectal cancer (mCRC), after failure of one to two prior lines of therapy for metastatic disease. A copy of the press release is included as Exhibit 99.1 to this Form 8-K and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

| Exhibit No. | Description |
|-------------|--|
| <u>99.1</u> | <u>Press release dated March 18, 2019.</u> |

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 18, 2019 Array BioPharma Inc.

By: /s/ JASON HADDOCK
Jason Haddock
Chief Financial Officer

